Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Thursday, UBS analysts, led by Kevin Caliendo, adjusted their outlook on ZimVie Inc. (NASDAQ:ZIMV) by reducing the price target on the company’s shares to $10.00 from the previous $16.00. Despite this change, they have decided to maintain a Neutral rating on the stock. The company’s shares, currently trading at $8.66, have declined significantly from their 52-week high of $22.40. According to InvestingPro analysis, ZimVie appears undervalued based on its Fair Value calculations.
The revision of the price target comes after considering the company’s performance and market conditions in the latter half of 2024. ZimVie, which operates in the premium segment of the market, showed some promising developments, such as an increase in implant volume growth in the third quarter and a rise in biomaterials sales in the fourth quarter. Management interpreted these as positive signs for future implant procedure volumes. While the company reported a revenue decline of 2.56% in the last twelve months, InvestingPro data shows strong liquidity with a current ratio of 2.14, indicating solid short-term financial health.
However, a decline in first-quarter sales in 2025 has tempered some of the initial optimism for a rapid recovery in the current year. While April did show some year-over-year implant volume growth in the United States, the analysts at UBS suggest a cautious approach when forecasting the industry’s performance for the remainder of the year. InvestingPro subscribers can access detailed analysis showing that while the company isn’t currently profitable, analysts expect it to return to profitability this year. Get access to 7 additional ProTips and comprehensive financial metrics with an InvestingPro subscription.
The UBS analyst shared his insights, stating, "The latter half of 2024 saw some green shoots at the premium end of the market where ZIMV operates, including positive implant volume growth in 3Q and a pick up in biomaterials sales in 4Q; whereas the dip in 1Q sales eased some of our own optimism for a more acute 2025 recovery." The company’s stock has shown high volatility with a beta of 2.02, suggesting significant price movements compared to the broader market.
Despite these mixed signals, April’s performance indicated some positive momentum, with an observed improvement in implant volume growth compared to the same period in the previous year. However, the overall industry outlook warrants caution, which is reflected in the analyst’s current stance on ZimVie Inc.
Investors and stakeholders of ZimVie Inc. will be monitoring the company’s performance closely, especially in light of the adjusted price target and the cautious industry outlook provided by UBS.
In other recent news, ZimVie Inc. reported its first-quarter financial results for 2025, revealing a mixed performance. The company achieved earnings per share of $0.27, surpassing the forecasted $0.2216 and marking a 238% increase year-over-year. Total (EPA:TTEF) revenue for the quarter was $112 million, representing a 5.2% decrease from the previous year. Despite the revenue decline, ZimVie demonstrated strong profitability with a 41% increase in adjusted EBITDA. The company has also provided optimistic full-year guidance, projecting revenue between $445 million and $460 million.
Additionally, ZimVie expanded its global reach by acquiring a distributor in Costa Rica for $3.3 million, a move expected to positively impact revenue and profit margins. Needham has maintained its Hold rating on ZimVie, highlighting the company’s solid profitability while adopting a cautious approach due to market challenges. The firm also noted ZimVie’s strategic focus on premium implants and digital solutions as a competitive advantage. These recent developments indicate ZimVie’s ongoing efforts to strengthen its market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.